Evaluate the clinical performance of RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (RESPOCT-ED study).

This study is a prospective, observational study to assess the clinical performance of the ZiP-CoVx-P2 point-of-care (POC) test for SARS-CoV-2 infection. The ZiP-CoVx-P2 test is performed on the ZiP-P2 instrument and uses isothermal nucleic acid amplification technology to detect SARS-CoV-2 RNA in combined oropharyngeal and bilateral mid-turbinate swabs. It provides results comparable to RT-PCR with a much faster turnaround time of 10-30 minutes for immediate clinical decision-making. The primary aim is to assess the clinical performance of the ZiP-CoVx-P2 test in detecting SARS-CoV-2 in oro-naso-pharyngeal swab samples from patients presenting to the emergency department with respiratory infection symptoms. Additionally, the study aims to evaluate the potential impact of this test on outcomes related to emergency department care. Participants will be asked to provide two swab samples immediately after in addition to any swabs taken for routine clinical care (i.e. rapid antigen test and RT-PCR). It will take approximately 3-5 minutes to extract additional swabs for the RESPOCT-ED study. Each sample will include oropharyngeal (throat) and bilateral mid-turbinate (nasal) sample and will be collected by healthcare staff. One swab will be tested using the ZiP-CoVx-P2 platform for SARS-CoV-2 detection within the emergency department and second swab will be bio banked. The RT-PCR and RAT test results will be retrieved from the medical records. The ZiP-CoVx-P2 test results are not provided back to the participants or are part of any clinical management. Clinical management will be based on the RT-PCR test results collected as part of routine clinical care.